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The role of PET/CT in the evaluation of bone marrow involvement in 
lymphoma patients at the initial staging
Lenfoma hastalarında tanı anında evreleme amaçlı çekilen PET/CT’nin kemik iliği 
infiltrasyonunu göstermedeki yeri
Fergun YILMAZ, Nur SOYER, Demet KİPER, Recep SAVAŞ, Nazan ÖZSAN, Fahri ŞAHİN, Güray SAYDAM,  
Mahmut TÖBÜ, Murat TOMBULOĞLU, Özgür ÖMÜR, Filiz VURAL
ÖZ
Amaç: Kemik iliği (Kİ) tutulumu, lenfoma hastalarında en 
önemli prognostik faktörlerden biridir. Bu nedenle, tanı anında Kİ 
tutulumunun gösterilmesi önemlidir.Kemik iliği biyopsisi (KİB) 
tutulumu göstermede altın standart kabul edilmesine rağmen 
invaziv ve ağrılı bir yöntemdir. Bu retrospektif çalışmada, tanı 
anında evreleme amacıyla çekilen PET/CT’nin Kİ tutulumunu 
göstermedeki yerini araştırdık.
Hastalar ve Yöntemler : Tanı anında PET/CT ve KİB yapılan 
hastalar çalışmaya alındı.
Bulgular: PET/CT’nin lenfoma hastalarının Kİ tutulumunu 
göstermedeki sensitivitesi %65.8, spesifisitesi ise %89.4 idi. 
Altgrup analizi yapıldığında; 176 Hodgkin lenfoma hastasında 
sensitivite %81 ve spesifisite %84 olarak bulundu. Negatif 
prediktif değer %98 idi. 201 diffüz büyük B hücreli lenfoma 
hastasında ise, sensitivite ve spesifisite sırasıyla %91.3 ve %94.3 
idi. Negatif prediktif değer %98.8 olarak hesaplandı.
Sonuç: PET/CT özellikle Hodgkin lenfoma ve difüz büyük B 
hücreli lenfoma hastalarında yüksek sensitivite ve spesifisitesi ile 
tamamlayıcı ve değerlendirilmesi gereken bir yöntemdir.
Anahtar kelimeler: PET/CT, Lenfoma, Kemik iliği tutulumu
Introduction
Lymphomas are the most common hematologic 
malignancies in the developed world. Bone marrow (BM) 
involvement occurs in 30-50% in non-Hodgkin lymphoma 
(NHL) patients, especially in indolent subtypes [1]. BM 
involvement is one of the most important prognostic factors 
in lymphomas. It increases the stage of the disease to stage 
4 according to Ann–Arbor staging system and is associated 
with poor prognosis [2]. Therefore, it is important to 
determine the presence of BM involvement in lymphoma 
patients at the time of diagnosis.
Bone marrow biopsy (BMB) is still accepted as the 
gold standard for evaluating the marrow. BMB is a painful 
ABSTRACT
Objective: Bone marrow (BM) involvement is one of the most 
important prognostic factors in lymphoma patients. Therefore, 
it is important to determine the presence of BM involvement in 
lymphoma patients at the time of diagnosis. Bone marrow biopsy 
(BMB) is still accepted as the gold standard for evaluating the 
marrow but it is painful and invasive. In this retrospective study, 
we aimed to evaluate the role of positron emission tomography 
combined with computed tomography (PET/CT) in evaluating the 
BM involvement in lymphoma patients at the initial staging.
Patients and Methods: The patients who were evaluated 
by PET/CT and bone marrow biopsy at time of diagnosis were 
enrolled in the study.
Results: The overall sensitivity of PET/CT in demonstrating 
BM involvement was 65.8%, and the specificity was 89.4%. In 
the subgroup analysis of 176 Hodgkin lymphoma (HL) patients, 
the sensitivity and specificity of the PET/CT were 81% and 
84% respectively. Negative predictive value was 98%. In 201 
diffuse large B cell lymphoma (DLBCL) patients, the sensitivity 
and specificity of the test were 91.3% and 94.3%, respectively. 
Negative predictive value was 98.8%.
Conclusion: PET/CT is an accurate and complementary 
modality with high specificity and sensitivity in detecting BM 
infiltration in HL and DLBCL patients.
Keywords: PET/CT, Lymphoma, Bone marrow infiltration
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and invasive procedure. Complications such as bleeding, 
infection, needle breakage, osteomyelitis and fractures, 
especially in osteoporotic patients can, though rarely, be 
seen (0.05-0.07%). Even mortality directly related to the 
procedure has been reported [3]. Another disadvantage of 
BMB is that, it gives data pertaining to a limited area that is 
biopsied. Since the infiltration of lymphoma is usually focal, 
biopsy can miss the infiltration and the size of the biopsy 
may be too small to evaluate the infiltration. Although, some 
studies support the need for bilateral biopsies [4], others 
concluded that a specimen long enough (approximately 2 
cm) may obviate the need for bilateral sampling [5].
New strategies are being searched for evaluating the BM 
infiltration in lymphoma patients. One of these methods is 
positron emission tomography combined with computed 
tomography (PET/CT) using 18F-2-deoxy-2-(18F)
fluoro-D-glucose (18F-FDG). It is a whole body imaging 
technique that gives functional information about the cells 
using the glucose metabolism. Metabolically active cells 
such as malignant cells use and take radio-labeled glucose 
more avidly and become visible. This method can be used 
for staging and assessing treatment response for various 
malignant tumors including aggressive NHL and Hodgkin 
lymphomas (HL) [6-8] but its role in demonstrating BM 
infiltration is not documented well at present. In this 
retrospective study, we compare the results of BMB and 
PET/CT in terms of BM infiltration in lymphoma patients.
Patients and Methods
Patients
Four hundred and eighty-six adult patients older than 18 
years of age diagnosed with lymphoma histopathologically 
according to World Health Organization (WHO) criteria [9] 
between March 2007 and August 2013 were retrospectively 
reviewed. PET/CT and BMB data obtained at the time 
of diagnosis of patients were re-assessed. Data of the 
patients were collected from the archives of Departments 
of Hematology and Pathology. Age, sex, complete blood 
count, lactate dehydrogenase and beta-2 microglobulin 
were recorded. The maximum time between the PET/CT 
and BMB was 7 days. The patients were excluded if their 
BMBs were performed more than 7 days after PET/CT.
Using WHO criteria, anemia was defined as hemoglobin 
lower than 130g/l and 120 g/l in males and females, 
respectively [10]. This study was approved by local ethics 
committee.
Bone Marrow Biopsy
BMBs were performed in the standard way from 
the iliac spine under local anesthesia. Patients with 
inadequate sample for interpretation were not enrolled 
in the study. Bone marrow sections were prepared and 
stained with haematoxylene-eosin after decalcification 
procedures of BMB specimens. All bone marrow biopsies 
were examined for infiltration of lymphoma by specialist 
hematopathologists. Using paraffin embedded whole tissue 
sections; immunohistochemical analysis was performed 
on an automated stainer (Ventana Benchmark XT; Ventana 
Medical Systems, Tucson, Arizona, USA) according to the 
standard protocols. Streptavidin-biotin-peroxidase detection 
system with diaminobenzidine (DAB) as chromogen was 
used to visualize bound secondary antibodies. In order to 
determine an infiltration, a panel of antibodies was used 
according to the initial diagnosis, which included CD3 
(Novacastra clone LN10, Novacastra Laboratories Ltd, 
Newcastle, UK; dilution 1:200), CD20 (Dako clone L26, 
DakoCytomation Inc, Carpenteria, CA; dilution 1:250), 
Pax-5 (CONE:34, Thermo Scientific Lab Vision, USA, 
dilution 1:50), CD30 (Novacastra clone 1G12, Novacastra 
Laboratories Ltd, Newcastle, UK; dilution 1:100), Bcl-2 
(Dako clone 124, DakoCytomation Inc, Carpenteria, CA; 
dilution 1:50). When necessary, other immunohistochemical 
analyses were also performed.
PET/CT
FDG PET and Contrast-Enhanced Computed 
Tomography
All patients underwent FDG-PET on a PET/CT unit 
(Discovery STE; GE, Milwaukee, USA). Patients fasted 
for at least 4 hours before imaging, and the glucose level 
in the peripheral blood was confirmed to be below 150 mg/
dL before FDG injection. 5.55 MBq/kg of body weight of 
FDG was administered intravenously (IV) an hour before 
the image acquisition. After the initial contrast-enhanced 
CT scan with 16-multidetector CT (GE), a standard PET 
protocol was used in the 3D mode to scan the area from the 
vertex of the skull to the pelvic region with an acquisition 
time of 3 minutes per bed position.
Scanning was performed using the helical technique 
after injection of contrast medium to the patients whilst in 
the supine position. A total dose of 100–130 mL iodinated 
contrast media (iopromide, Bayer Pharma AG, Berlin 
,Germany) was administered IV at a rate of 3 mL/s by an 
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automatic injector. Written informed consents were obtained 
before PET/CT examination from each patient.
Image Analysis
 Fluoro-D-Glucose/positron emmision tomography 
images were viewed at interactive workstations 
(Advantage Workstation AW4.6, GE Healthcare) by the 
same consultant in nuclear medicine and same radiologist 
both of whom are experienced in oncological imaging. 
Bone marrow FDG uptake was assessed visually in 
comparison to the liver uptake. The standardized uptake 
value (SUV) measurements were also obtained for each 
of the 3 larger homogeneous vertebrae visible in the field 
of view (L3, L4, and L5 or S1). A region of interest (ROI) 
was drawn over the vertebral body, using an automatic 
isocontour ROI set at 75% of the maximum SUV. The 
bone marrow SUV was defined as the mean value of 
the 3 selected vertebrae; vertebrae SUV values higher 
than the liver were considered as a sign of bone marrow 
involvement [11]. The absence of tracer uptake or low-
grade uptake (less than or equal to liver parenchyma 
intensity) in the marrow sites was interpreted as absence 
of disease activity. Tracer uptake of moderate to intense 
degree (more than liver parenchyma intensity) was 
interpreted as presence of disease involvement. This was 
performed as a ratio of SUVmax values obtained from a 
suitable circular ROI over the spine in patients with bone 
marrow tracer uptake interpreted as presence of disease 
metabolic activity on qualitative assessment.
Statistical analysis
Continuous data were expressed as median (minimum- 
maximum), and qualitative data were expressed as number of 
cases and percentages. Patients were categorized according 
to the status of BM infiltration according to the BMB and 
18F-FDG PET/CT results. Correlations between FDG PET/
CT and available pathological findings were examined. All 
positive pathological findings of BMB were considered 
as true-positive results. A finding of abnormal focal or 
multifocal increase in FDG uptake by the BM in the initial 
PET/CT study was considered true positive if the patient 
had corresponding pathologically confirmed lymphoma 
with BMB. Sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) of FDG PET/
CT against BMB were presented for the assessment of BM 
involvement by lymphoma.
Results
Four hundred and eighty-six newly diagnosed lymphoma 
patients (208 females, 278 males) who underwent both PET/
CT and BMB were evaluated retrospectively. The median 
age was 45 years (range: 18-87 years). BM infiltration was 
documented in 79 patients with BMB, 95 patients with 
PET/CT and 52 patients with both procedures. There was 
discordance between the procedures in 70 patients (43 
patients with negative BM infiltration and positive PET/
CT; 27 patients with negative PET/CT for BM involvement 
but positive BMB). The characteristics of the patients were 
summarized in Table I.
Table I: Characteristics of the patients
All patients Non-Hodgkin
lymphoma
Hodgkin 
lymphoma
Number of patients 486 310 176
Age, years (range) 45 (18-87) 59 (18-87) 38 (18-79)
Sex (male/female) (278/208) (173/137) (105/71)
Involvement in PET/CT (yes/no) 95/391 60/250 35/141
Involvement in BMB (yes/no) 78/408 67/243 11/165
Anemia (yes/no) 178/181* 106/119* 72/62*
Beta 2 level (normal/high) 108/53* 71/38* 37/15*
LDH level (normal /high ) 236/139* 145/95* 91/44*
* Data of other patients are not available, PET/CT: positron emission to-
mography combined with computed tomography, BMB: bone marrow bi-
opsy, LDH: lactate dehydrogenase
Since the BMB is still regarded as gold standard 
for evaluating BM infiltration, we compared the PET/
CT imaging findings with BMB results in terms of 
BM infiltration. The overall sensitivity of PET/CT in 
demonstrating BM involvement in all lymphoma patients 
was 65.8%, and the specificity was 89.4%. As the lymphoma 
patients were very heterogeneous, we performed subgroup 
analysis, separating HL and NHL patients.
HL Patients
There were 176 (71 females, 105 males) HL patients with 
the median age of 38 years (range: 18-79 years). BM 
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infiltration was documented in 11 HL patients with BMB 
while PET/CT depicted a high SUV value consistent with 
BM infiltration in 35 patients. The tests were comparable in 
148 patients (both documented infiltration in 9 patients and 
neither documented infiltration in 139 patients). There was 
discordance between the tests in 28 of HL patients (Table 
II).
Table II: The results of PET/CT and BMB in HL patients
PET/CT infiltration
YES NO
BMB 
infiltration
YES
NO
9 2
26 138
BMB: bone marrow biopsy, PET/CT: positron emission tomography com-
bined with computed tomography, HL: Hodgkin lymphoma patients
Although the BMB was negative for infiltration, PET/
CT depicted high uptake (more than liver); in 26 patients 
with HL which can be interpreted in favor of involvement. 
In three of these patients, the BM was hypercellular without 
infiltration. Twenty patients were either anemic or had 
leukocytosis (>10000/mm3). The laboratory tests were 
consistent with iron deficiency anemia in 6 of the anemic 
patients and anemia of chronic disease in the remaining 
anemic patients. The discordance could not be accounted 
for in 3 patients.
Among the HL patients, the sensitivity and specificity 
of the test were 81% and 84%, respectively. False 
positivity and false negativity was calculated as 18% and 
16%, respectively. PPV and NPV was 25.7% and 98%, 
respectively (Table III).
NHL Patients
The subgroup of NHL patients comprised of 310 patients 
with diffuse large B cell lymphoma (DBBCL- 201 patients), 
follicular lymphoma (22 patients), mantle cell lymphoma 
(18 patients), marginal zone lymphoma (12 patients), 
low grade B cell lymphoma- nonspecified ( 3 patients), 
T- cell lymphoma (11 patients), anaplastic large B cell 
lymphoma (13 patients), Burkitt lymphoma (9 patients), 
small lymphocytic lymphoma (21 patients) were analyzed 
retrospectively. The most common subtype was DBBCL. 
Since high and low grade lymphomas were heterogeneous 
groups, the subgroup analysis in NHL patients was 
performed for the DLBCL group.
There were 201 DLBCL patients (88 females and 113 
males). The median age was 59 years (range: 21-87 years). 
In 178 DLBCL patients, BMB showed no infiltration while 
in 23 patients it revealed lymphoma infiltration. PET/CT 
and BMB were consistent in 189 patients (21 patients were 
reported having BM involvement with both tests and there 
was no BM infiltration with either test in 168 patients). 
There was discordance between the tests in 12 patients 
(Table IV). There were two patients in whom PET/CT 
missed the infiltration of BM documented by biopsy. In 10 
patients, PET/CT indicated infiltration while it could not 
be confirmed by BMB. Five of them had anemia consistent 
with chronic disease, three of them had leukocytosis and 2 
of them had thrombocytosis which could explain the high 
activity of the bone marrow and positive PET/CT results.
In subgroup analysis of the DLBCL patients showed that 
the sensitivity and specificity of the test were 91.3% and 
94.3%, respectively. False positivity and false negativity 
was calculated as 5.6% and 8.6%, respectively. PPV and 
NPV were 67.7% and 98.8%, respectively (Table III). There 
was not a spesific subgroup in DLBCL patients with a 
higher spesificity or sensitivity.
Table III: Statistical measures of the performance of PET/CT (%) in HL patients and DLBCL
Sensitivity Specificity False negative ratio False positive ratio Accuracy Positive 
predictive value
Negative 
predictive value
HL 81 84 16 18 84 25.7 98
DLBCL 91.3 94.3 8.6 5.6 94 67.7 98.8
HL: Hodgkin lymphoma, DLBCL: diffuse large B cell lymphoma, PET/CT: positron emission tomography combined with computed tomography
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Table IV: The results of PET/CT and BMB in DLBCL patients
PET/CT infiltration
YES NO
BMB 
infiltration
YES
NO
21 2
10 168
BMB: bone marrow biopsy, PET/CT: positron emission tomography com-
bined with computed tomography, DLBCL: diffuse large B cell lymphoma
Discussion
Positron emission tomography combined with computed 
tomography is being used increasingly for the initial 
staging and response evaluation in lymphoma patients. 
Although, its overall usefulness is not well documented 
in low-grade lymphomas, its role is well established in 
staging and response evaluation in HL and aggressive NHL 
patients [12,13]. Its value in showing the BM infiltration 
in lymphoma patients remains unclear and BMB is still the 
gold standard for evaluating the infiltration although it has 
some limitations. In this retrospective study, we compared 
the demonstration of BM infiltration with BMB and PET/ 
CT which were performed at the time of diagnosis. Because 
FDG uptake can be affected by various chemotherapies and 
granulocyte stimulating factors, PET/CT reports obtained 
before the onset of the therapy were taken into account. The 
overall sensitivity and specificity of PET/CT against BMB 
was calculated as 65.8% and 89.4%, respectively. A meta-
analysis performed by Pakos et al. found the sensitivity and 
specificity as 51% and 91%, respectively [14]. In this meta-
analysis, no major subgroup differences have been reported 
in retrospective and prospective studies and the better 
sensitivity was shown in HL and aggressive NHL patients, a 
finding which is in agreement with our results [14].
Subgroup analysis of HL patients showed that the 
sensitivity and specificity of the PET/CT were 81% and 
84%, respectively. In various research studies and meta-
analyses conducted on HL patients, the sensitivity is in the 
range of 78.6-100%, which is consistent with our results. 
The specificity is also high, ranging between 76.5 – 100% 
[15-18].
In 26 patients, although the BMB was negative for 
infiltration, PET/CT showed high FDG uptake which 
may be an indicator of BM involvement. In these patients, 
leukocytosis, anemia and hypercellular bone marrow were 
noted. High uptake may be related to active bone marrow 
rather than infiltration. But due to the fact that it was a 
retrospective study, we were unable to perform a rebiopsy 
from the sites of high FDG uptake to re-assess the infiltration. 
In a meta–analysis, 6 of 12 patients with negative BMB and 
positive PET/CT were found to be positive in BMB when 
the biopsies were repeated according to PET/CT uptake 
signals [14].
Positive predictive value and NPV of PET/ CT in HL 
patients were 25.7% and 98% in our study. Muzahir et al., 
reported PPV and NPV to be 29.72% and 76.57% [16]. In 
a recent meta–analysis, pooled PPV and NPV as high as 
97.6% and 98.8%, respectively have been reported [15]. 
Although, the NPV calculated in our study is consistent 
with this analysis, PPV is lower in the present study. In the 
present study, we took BMB as gold standard for evaluating 
BM infiltration. Therefore, we considered some FDG-
avid lesions in PET/CT which could be indicative of true 
infiltration as false positive based on the negative results in 
blind BMB. Furthermore, it should be noted that the BMB 
may not show all the lymphomatous infiltration. BMB 
may reveal positive infiltration if the biopsy is repeated 
according to FDG-avid sites. This may explain the low PPV 
in our study [15,16,19,20].
Non-Hodgkin lymphoma is a heterogeneous group 
of patients with low and high grade lymphomas with 
different properties. In the literature, there was a significant 
difference in the capability of PET/CT to detect BM 
infiltration according to histological type of NHL. It has 
been reported in the literature that the performance of PET/
CT in evaluating the BM infiltration in indolent lymphomas 
was poor [18, 21]. Since, indolent lymphomas comprise a 
number of different lymphoma types, we did not perform a 
subgroup analysis in this heterogeneous group.
Chen and et al., reported that the performance of 
PET/CT was better in the aggressive lymphoma group 
[21]. Among the aggressive lymphoma patients, DLBCL 
patients constituted the majority of the patients (201 
patients, 64% of all NHL). Therefore, in this retrospective 
analysis, DLBCL were chosen for subgroup analysis 
among aggressive lymphoma patients. The sensitivity and 
specificity of the test against BMB were 91.3% and 94.3% 
respectively. There was discordance in 12 (6%) patients. 
PPV and NPV were 67.7% and 98.8%, respectively. 
Cortés-Romera et al., analyzed 147 lymphoma patients 
(84 DLBCL, 63 HL) [22]. The concordant and discordant 
results were observed between PET/CT and BMB in 
19 (14%) and 128 patients (87%), respectively. The 
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sensitivity, specificity, accuracy, as well as PPV and NPV 
of FDG-PET/CT for the detection of BM infiltration 
were 95%, 86%, 87%, 54%, and 99%, respectively. In a 
meta-analysis with newly diagnosed DLBCL patients, the 
sensitivity of FDG PET/CT for detecting BM involvement 
ranged between 70.8% to 95.8% while the specificity was 
in the range of 99.0% to 100%, with pooled estimates of 
88.7% (95% confidence interval, CI, 82.5 - 93.3%) and 
99.8% (95% CI, 98.8 - 100%), respectively [23]. These 
results are comparable to ours.
In 10 DLBCL patients, PET/CT revealed infiltration 
while could not be confirmed by BMB. Five of these patients 
had anemia consistent with chronic disease, three patients 
had leukocytosis and two patients had thrombocytosis, 
which all can be held accountable for high activity of the 
bone marrow and positive PET/CT results. Positive results 
in PET/CT should be interpreted carefully if they are not 
confirmed by biopsy because false positive results may 
be due to chemotherapy, granulocyte colony stimulating 
factors, infection/inflammation, or hyperplastic bone 
marrow [24, 25].
False negative results with BMB due to focal infiltration 
should also be taken into account and repeat biopsy should 
be considered for the FDG-avid sites. PET/CT guided 
biopsy will increase the accuracy of BMB [19].
In our study, PET/CT missed the infiltration in 2 patients 
with DLBCL and 2 patients with HL. False negative results 
may be due to diffuse low density marrow involvement or 
low FDG uptake per cell [12, 21].
In the light of these data, PET / CT is an accurate and 
complementary test with high specificity and sensitivity 
in detecting BM infiltration, which also gives a prognostic 
information in DLBCL and HL patients [23, 26, 27]. On 
the other hand, there are also studies in which the authors 
argued that PET/CT had limited value in detecting BM 
involvement [28].
There are limitations of the present study. First, it was a 
retrospective study on a heterogeneous group of patients at 
different stages of diseases. Second, the unilateral iliac crest 
biopsies were carried out blindly and we could not perform 
a repeat biopsy in patients with negative BMB and positive 
PET/CT results, which may be the source of the lower PPV 
of the PET/CT. Lastly, since this retrospective study did not 
involve the follow up period of the patients, the effect of 
bone marrow involvement detected by PET/CT on survival 
and response rates could not be determined.
In conclusion, although BMB is still the gold standard 
to assess BM infiltration in lymphoma patients, it is a 
painful and stressful procedure for the patients. It is mostly 
considered safe but adverse effects such as hemorrhage, 
infection are also reported. Hence, since PET/CT is a 
noninvasive, painless and more comfortable procedure 
than biopsy, it could be an alternative to BMB for initial 
staging in especially HL and DBBCL patients in the future. 
However, prospective studies with larger sample size, more 
homogenous groups and involving follow-up periods are 
needed to detect the performance of PET/CT in establishing 
the infiltration and its effects on survival.
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